Insight Molecular Diagnostics (IMDX) Operating Margin (2020 - 2025)
Insight Molecular Diagnostics (IMDX) has disclosed Operating Margin for 6 consecutive years, with 1505.0% as the latest value for Q4 2025.
- Quarterly Operating Margin rose 376792.0% to 1505.0% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 260.1% through Dec 2025, up 298504.0% year-over-year, with the annual reading at 260.1% for FY2025, 298504.0% up from the prior year.
- Operating Margin hit 1505.0% in Q4 2025 for Insight Molecular Diagnostics, up from 4249.23% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 1969.7% in Q1 2023 to a low of 11752.17% in Q3 2024.
- Historically, Operating Margin has averaged 2376.1% across 5 years, with a median of 1654.77% in 2023.
- Biggest five-year swings in Operating Margin: soared 5168307bps in 2021 and later tumbled -1023399bps in 2024.
- Year by year, Operating Margin stood at 994.15% in 2021, then plummeted by -328bps to 4251.09% in 2022, then dropped by -21bps to 5152.55% in 2023, then skyrocketed by 56bps to 2262.92% in 2024, then soared by 167bps to 1505.0% in 2025.
- Business Quant data shows Operating Margin for IMDX at 1505.0% in Q4 2025, 4249.23% in Q3 2025, and 1900.0% in Q2 2025.